Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sopherion names new senior EVP of clinical affairs
Prior to joining Sopherion, Dr Rozencweig was a key clinical development consultant to the company and a member of the Sopherion protocol development team for Myocet. Dr Rozencweig
Prior to joining Sopherion, Dr Rozencweig was a key clinical development consultant to the company and a member of the Sopherion protocol development team for Myocet. Dr Rozencweig
The company also announced the first enrollment in its multi-center, randomized clinical trial of deep brain stimulation (DBS) for treatment-resistant depression. Medtronic is proceeding with the FDA investigational
Since November 2000, he has been managing director of MPM BioEquities and serves as portfolio manager for the MPM BioEquities Fund. From July 1989 to November 2000, he
The company reported a net loss available to common shareholders of $320.3 million, or $1.05 per diluted share, for the year ended December 31, 2008, compared to a
The company has a number of ready to partner preclinical and early clinical projects focused on improving oral, sublingual and transdermal medication. Orexo will acquire the company for
Shire’s new office will serve as the base for preparations for the future commercialization of its pipeline products in Japan. In his new role, Mr Fujiwara will oversee
This acquisition will broaden the scope of Shire’s attention deficit hyperactivity disorder (ADHD) portfolio and will facilitate immediate access to the European ADHD market as well as provide
Texcel Medical said that, in this role, Mr Smith will oversee all functions at the company, which helps companies around the world by providing the manufacturing infrastructure and
Prior to joining PolyRemedy, Mr Jones served as COO at Reliant Technologies, a medical device company. Previously, Mr Jones was COO at LuMend, an interventional cardiology medical device
The European approval of Valdoxan is based on both short- and long-term results from a large, comprehensive, international development program including almost 6,000 adult patients with depression, said